Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Increasing Precision in Cancer Cell Death to Prevent Metastasis In housework and lawn work, it is important to have the right tool for the job.
The Neuroendocrine Tumor Research Foundation (NETRF) announces a new NETRF Mentored Award for early career researchers, supported by Ipsen. The two-year grant for those in
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
Clarivate Analytics has released the most influential researcher list for 2018, which identifies exceptional researchers whose highly cited work is among the top 1% in their field around the world.
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
